DBV Technologies (DBVT)

• Market cap: $268M
• 1 day: 0.00%
• 5 days: -1.31%
• 1 month: 0.62%
• 3 months: 5.38%
• 6 months: 134.77%
• Year to date: 201.23%
• 1 year: 117.56%
• 5 years: -53.60%
• 10 years: -97.50%
• Sector: Healthcare
• Industry: Biotechnology

About: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Employees: 109

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

293% more capital invested

Capital invested by funds: $16.8M [Q1] → $66.2M (+$49.4M) [Q2]

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

65% more funds holding

Funds holding: 17 [Q1] → 28 (+11) [Q2]

24.01% more ownership

Funds ownership: 2.4% [Q1] → 26.41% (+24.01%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7.25 26% downside
• Avg. target: $14.13 44% upside
• High target: $21 115% upside

2 analyst ratings

• positive: 1 50%
• neutral: 0 0%
• negative: 1 50%

JMP Securities Jonathan Wolleben	115% upside $21	Market Outperform Reiterated	26 Jun 2025
Goldman Sachs Rajan Sharma	26% downside $7.25	Sell Reinstated	29 May 2025